$KRON
Kronos Bio, Inc. Stock $kron

$kron Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000174183023000031 Filed on May 10, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q4
Revenue	$1.900M	$1.200M	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$12.53M	$10.82M	$11.28M
YoY Change	8.12%	-14.74%	-8.68%
% of Gross Profit
Research & Development	$22.67M	$19.66M	$22.40M
YoY Change	-0.15%	-19.56%	-55.25%
% of Gross Profit
Depreciation & Amortization	$600.0K	$600.0K	$574.0K
YoY Change	0.0%	0.0%	5.13%
% of Gross Profit
Operating Expenses	$34.03M	$29.71M	$33.68M
YoY Change	1.5%	-18.29%	-46.03%
Operating Profit	-$32.17M	-$28.49M
YoY Change	-4.06%	-21.65%
Interest Expense	$2.427M	$2.255M	$1.900M
YoY Change	287.08%	2110.78%	2538.89%
% of Operating Profit
Other Income/Expense, Net	$2.427M	$2.255M
YoY Change	287.08%	2110.78%
Pretax Income	-$29.74M	-$26.24M	-$31.78M
YoY Change	-9.61%	-27.65%	-49.01%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$29.74M	-$26.24M	-$31.78M
YoY Change	-9.61%	-27.65%	-49.01%
Net Earnings / Revenue	-1565.32%	-2186.5%
Basic Earnings Per Share	-$0.52	-$0.46
Diluted Earnings Per Share	-$0.52	-$0.46	-$0.56
COMMON SHARES
Basic Shares Outstanding	57.63M shares	57.63M shares	56.90M shares
Diluted Shares Outstanding	57.40M shares	57.15M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$219.5M	$226.4M	$238.2M
YoY Change	-18.08%	-25.31%	-29.84%
Cash & Equivalents	$44.40M	$61.65M	$75.97M
Short-Term Investments	$175.1M	$164.8M	$162.2M
Other Short-Term Assets	$4.319M	$5.350M	$5.534M
YoY Change	-31.89%	-21.25%	-23.45%
Inventory
Prepaid Expenses
Receivables	$343.0K	$516.0K	$572.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$224.1M	$232.3M	$244.3M
YoY Change	-18.43%	-25.22%	-29.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.81M	$12.53M	$12.99M
YoY Change	-70.35%	-69.35%	-68.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$244.0K	$14.89M	$9.762M
YoY Change	-99.0%	21.55%
Other Assets	$1.167M	$1.169M	$1.167M
YoY Change	941.96%	934.51%	941.96%
Total Long-Term Assets	$36.49M	$56.76M	$50.65M
YoY Change	-45.08%	2.7%	15.31%
TOTAL ASSETS
Total Short-Term Assets	$224.1M	$232.3M	$244.3M
Total Long-Term Assets	$36.49M	$56.76M	$50.65M
Total Assets	$260.6M	$289.0M	$294.9M
YoY Change	-23.62%	-21.0%	-24.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.676M	$6.039M	$5.047M
YoY Change	-18.64%	27.97%	405.71%
Accrued Expenses	$6.936M	$6.598M	$12.96M
YoY Change	-33.76%	-20.77%	43.03%
Deferred Revenue	$8.824M	$8.655M	$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$22.06M	$25.26M	$21.49M
YoY Change	20.98%	47.93%	57.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$87.00K	$209.0K
YoY Change	-100.0%	-89.06%	-81.0%
Total Long-Term Liabilities	$0.00	$87.00K	$209.0K
YoY Change	-100.0%	-89.06%	-81.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.06M	$25.26M	$21.49M
Total Long-Term Liabilities	$0.00	$87.00K	$209.0K
Total Liabilities	$57.27M	$63.42M	$50.44M
YoY Change	16.94%	29.86%	8.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$452.2M	-$422.4M	-$396.2M
YoY Change	36.14%	41.15%	50.66%
Common Stock	$58.00K	$57.00K	$57.00K
YoY Change	3.57%	1.79%	1.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$203.3M	$225.6M	$244.5M
YoY Change
Total Liabilities & Shareholders Equity	$260.6M	$289.0M	$294.9M
YoY Change	-23.62%	-21.0%	-24.66%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	-$29.74M	-$26.24M	-$31.78M
YoY Change	-9.61%	-27.65%	-49.01%
Depreciation, Depletion And Amortization	$600.0K	$600.0K	$574.0K
YoY Change	0.0%	0.0%	5.13%
Cash From Operating Activities	-$25.03M	-$5.947M	-$22.53M
YoY Change	11.12%	-74.68%	-61.51%
INVESTING ACTIVITIES
Capital Expenditures	$308.0K	$126.0K	$52.00K
YoY Change	-458.14%	-65.57%	-110.88%
Acquisitions
YoY Change
Other Investing Activities	$5.682M	-$6.229M	$31.79M
YoY Change	-113.98%	-76.01%	-18.96%
Cash From Investing Activities	$5.374M	-$6.355M	$31.74M
YoY Change	-113.19%	-75.87%	-18.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	376.0K	$0.00	-716.0K
YoY Change	-8.29%	-100.0%	-168.19%
NET CHANGE
Cash From Operating Activities	-25.03M	-$5.947M	-22.53M
Cash From Investing Activities	5.374M	-$6.355M	31.74M
Cash From Financing Activities	376.0K	$0.00	-716.0K
Net Change In Cash	-19.28M	-$12.30M	8.492M
YoY Change	-69.33%	-75.04%	-145.36%
FREE CASH FLOW
Cash From Operating Activities	-$25.03M	-$5.947M	-$22.53M
Capital Expenditures	$308.0K	$126.0K	$52.00K
Free Cash Flow	-$25.33M	-$6.073M	-$22.58M
YoY Change	12.92%	-74.54%	-61.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001741830
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-39592
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Kronos Bio, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-1895605
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1300 So. El Camino Real
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 400
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Mateo
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94402
CY2023Q1	dei	City Area Code CityAreaCode	650
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	781-5200
CY2023Q1	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value per share
CY2023Q1	dei	Trading Symbol TradingSymbol	KRON
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57630464	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61646000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75973000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	164756000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	162212000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5866000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6106000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	232268000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	244291000	usd
CY2023Q1	us-gaap	Long Term Investments LongTermInvestments	14885000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	9762000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12529000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12985000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24123000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24707000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4051000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2026000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1169000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1167000	usd
CY2023Q1	us-gaap	Assets Assets	289025000	usd
CY2022Q4	us-gaap	Assets Assets	294938000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6039000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5047000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6598000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12963000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3032000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2347000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8655000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	940000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1129000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	25264000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21486000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27945000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28744000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	10124000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	87000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	209000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	63420000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	50439000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57353754	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57353754	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56967436	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56967436	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	57000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	57000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	648334000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	641422000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-422426000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-396188000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-360000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-792000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	225605000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	244499000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	289025000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	294938000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1221000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19658000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24438000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10056000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11927000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	29714000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	36365000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-28493000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-36365000	usd
CY2023Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	2255000	usd
CY2022Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	102000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2255000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	102000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-26238000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-36263000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	432000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-131000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25806000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36394000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57147253	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57147253	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55839336	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55839336	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	244499000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	305000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6607000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	432000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-26238000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	225605000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	345097000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	529000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7788000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-131000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-36263000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	317020000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-26238000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-36263000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	569000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	557000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1253000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-517000	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-212000	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-343000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6607000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7788000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	585000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	534000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-274000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-406000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1005000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3670000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6365000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-505000	usd
CY2023Q1	kron	Increase Decrease In Right Of Use Operating Assets And Liabilities Net IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet	115000	usd
CY2022Q1	kron	Increase Decrease In Right Of Use Operating Assets And Liabilities Net IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet	297000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	18779000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-5000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-233000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5947000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23484000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	126000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	366000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	102595000	usd
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	94544000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	96366000	usd
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	68574000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4051000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6355000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-26336000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	529000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	529000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12302000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-49291000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77999000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	200296000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65697000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	151005000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	7000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	47000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61646000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	148979000	usd
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2026000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65697000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	151005000	usd
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-422400000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed financial statements include, but are not limited to, revenue, the accrual of research and development expenses, the fair value of investments, income tax uncertainties, the valuation of equity instruments and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates.</span></div>
CY2023Q1	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Current CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent	232188000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	58000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	417000	usd
CY2023Q1	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Excluding Accrued Interest Current CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	231829000	usd
CY2022Q4	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Current CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent	234344000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	800000	usd
CY2022Q4	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Excluding Accrued Interest Current CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	233551000	usd
CY2023Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	52188000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	61577000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	164756000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	162212000	usd
CY2023Q1	us-gaap	Long Term Investments LongTermInvestments	14885000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	9762000	usd
CY2023Q1	us-gaap	Investments And Cash InvestmentsAndCash	231829000	usd
CY2022Q4	us-gaap	Investments And Cash InvestmentsAndCash	233551000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	164995000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	174786000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue	14885000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue	9762000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	179880000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	184548000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	9800000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	usd
CY2023Q1	kron	Debt Securities Available For Sale Accrued Interest DebtSecuritiesAvailableForSaleAccruedInterest	516000	usd
CY2022Q4	kron	Debt Securities Available For Sale Accrued Interest DebtSecuritiesAvailableForSaleAccruedInterest	572000	usd
CY2023Q1	kron	Prepaid Equipment Service Contracts PrepaidEquipmentServiceContracts	307000	usd
CY2022Q4	kron	Prepaid Equipment Service Contracts PrepaidEquipmentServiceContracts	289000	usd
CY2023Q1	kron	Prepaid External Research And Development And Outside Services PrepaidExternalResearchAndDevelopmentAndOutsideServices	1747000	usd
CY2022Q4	kron	Prepaid External Research And Development And Outside Services PrepaidExternalResearchAndDevelopmentAndOutsideServices	2276000	usd
CY2023Q1	kron	Prepaid Software PrepaidSoftware	1297000	usd
CY2022Q4	kron	Prepaid Software PrepaidSoftware	905000	usd
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	1124000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1630000	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	875000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	434000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5866000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6106000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18613000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18500000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6084000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5515000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12529000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12985000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	600000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	600000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1238000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4277000	usd
CY2023Q1	kron	Accrued External Research And Development Current AccruedExternalResearchAndDevelopmentCurrent	4139000	usd
CY2022Q4	kron	Accrued External Research And Development Current AccruedExternalResearchAndDevelopmentCurrent	7694000	usd
CY2023Q1	kron	Accrued Outside Services Current AccruedOutsideServicesCurrent	916000	usd
CY2022Q4	kron	Accrued Outside Services Current AccruedOutsideServicesCurrent	945000	usd
CY2023Q1	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	40000	usd
CY2022Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	40000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	265000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6598000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12963000	usd
CY2023Q1	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	708000	usd
CY2022Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	891000	usd
CY2023Q1	kron	Espp Withholdings Liability Current ESPPWithholdingsLiabilityCurrent	232000	usd
CY2022Q4	kron	Espp Withholdings Liability Current ESPPWithholdingsLiabilityCurrent	238000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	940000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1129000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7454665	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.83
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2385324	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.08
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	504408	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.97
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	82094	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.72
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9253487	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.38
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y11M23D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	44000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.49
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	29800000	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	35400000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6607000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7788000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-26238000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-36263000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57147253	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57147253	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55839336	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55839336	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13219396	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9962346	shares
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24123000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24707000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3032000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2347000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27945000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28744000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	30977000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	31091000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7013000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1278000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1278000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	900000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1000000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	4211000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5749000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1327000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5405000	usd
CY2023Q1	kron	Lessee Operating Lease Liability To Be Paid Year Four And Thereafter LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter	21298000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	37990000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	30977000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1200000	usd

Files In Submission

Name	View Source	Status
0001741830-23-000031-index-headers.html	Edgar Link	pending
0001741830-23-000031-index.html	Edgar Link	pending
0001741830-23-000031.txt	Edgar Link	pending
0001741830-23-000031-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
kron-20230331.htm	Edgar Link	pending
kron-20230331.xsd	Edgar Link	pending
kron-20230331_g1.jpg	Edgar Link	pending
kronq1fy2023ex311.htm	Edgar Link	pending
kronq1fy2023ex312.htm	Edgar Link	pending
kronq1fy2023ex321.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
kron-20230331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
kron-20230331_def.xml	Edgar Link	unprocessable
kron-20230331_pre.xml	Edgar Link	unprocessable
kron-20230331_lab.xml	Edgar Link	unprocessable
kron-20230331_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KRON
Kronos Bio, Inc. Stock $kron

2023 Q2 Form 10-Q Financial Statement

#000174183023000031 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KRON Kronos Bio, Inc. Stock $kron

2023 Q2 Form 10-Q Financial Statement

#000174183023000031 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KRON
Kronos Bio, Inc. Stock $kron